Jasper Therapeutics Overview
Jasper Therapeutics (JSPR) has a P/E ratio of -0.39, below the sector sector average of 35.6.
Get informed when a big investor buys or sells
+ Follow-0.39
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Jasper Therapeutics (JSPR) currently reports a P/E ratio of -0.39. That is below the sector sector average of 35.6. Use the charts on this page to explore Jasper Therapeutics's P/E ratio history and peer comparisons.
Jasper Therapeutics's P/E ratio of -0.39 is lower than the its sector sector average of 35.6. That is roughly 101.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Jasper Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -0.39, JSPR can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -0.39, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 35.6. From there, open related valuation or income-statement pages for Jasper Therapeutics, and consider following JSPR for alerts when major investors trade the stock.
